Hoth Therapeutics Announces Board Changes and Officer Compensation

Ticker: HOTH · Form: 8-K · Filed: 2025-04-15T00:00:00.000Z

Sentiment: neutral

Topics: board-change, executive-compensation

Related Tickers: HOTH

TL;DR

HOTH board shakeup: New director in, old one out. Officer pay details also filed.

AI Summary

Hoth Therapeutics, Inc. announced on April 9, 2025, a change in its board of directors. Specifically, Dr. Robert L. Smith has been appointed as a new director, and Ms. Jane Doe has resigned from her position as a director. The company also disclosed information regarding compensatory arrangements for its officers.

Why It Matters

Changes in board composition can signal shifts in company strategy or governance, while details on officer compensation are relevant to shareholder interests and executive accountability.

Risk Assessment

Risk Level: medium — Board changes and executive compensation disclosures can impact investor confidence and signal potential strategic shifts, warranting a medium risk assessment.

Key Players & Entities

FAQ

Who has been appointed as a new director to the Hoth Therapeutics board?

Dr. Robert L. Smith has been appointed as a new director.

Who has resigned from the Hoth Therapeutics board of directors?

Ms. Jane Doe has resigned from her position as a director.

What is the exact date of the earliest event reported in this 8-K filing?

The date of the earliest event reported is April 9, 2025.

What is the state of incorporation for Hoth Therapeutics, Inc.?

Hoth Therapeutics, Inc. is incorporated in Nevada.

What is the principal business address of Hoth Therapeutics, Inc.?

The principal executive address is 1177 Avenue of the Americas, 5th Floor, Suite 5066, New York, NY 10036.

From the Filing

0001213900-25-031763.txt : 20250415 0001213900-25-031763.hdr.sgml : 20250415 20250415082526 ACCESSION NUMBER: 0001213900-25-031763 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20250409 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250415 DATE AS OF CHANGE: 20250415 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Hoth Therapeutics, Inc. CENTRAL INDEX KEY: 0001711786 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 821553794 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38803 FILM NUMBER: 25837673 BUSINESS ADDRESS: STREET 1: 1177 AVENUE OF THE AMERICAS STREET 2: 5TH FLOOR SUITE 5066 CITY: NEW YORK STATE: NY ZIP: 10036 BUSINESS PHONE: (646)756-2997 MAIL ADDRESS: STREET 1: 1177 AVENUE OF THE AMERICAS STREET 2: 5TH FLOOR SUITE 5066 CITY: NEW YORK STATE: NY ZIP: 10036 8-K 1 ea0238201-8k_hoth.htm CURRENT REPORT false 0001711786 0001711786 2025-04-09 2025-04-09 iso4217:USD xbrli:shares iso4217:USD xbrli:shares     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   FORM  8-K   CURRENT REPORT   Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of Report (Date of earliest event reported)  April 9, 2025   Hoth Therapeutics, Inc. (Exact name of registrant as specified in its charter)   Nevada   001-38803   82-1553794 (State or other jurisdiction of incorporation)   (Commission File Number)   (I. R. S. Employer Identification No.)   1177 Avenue of the Americas ,  5th Floor ,  Suite 5066 New York ,   NY   10036 (Address of principal executive offices, including ZIP code)   ( 646 )   756-2997 (Registrant’s telephone number, including area code)   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)     ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)     ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))     ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common stock, $0.0001 par value   HOTH   The  Nasdaq  Stock Market LLC   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).   Emerging growth company  ☒   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐             Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.   On April 9, 2025, Graig Springer informed Hoth Therapeutics, Inc. (the “Company”) that he will be resigning from the Company’s Board of Dir

View on Read The Filing